Agile Therapeutics, Inc. (AGRX) |
|
1.805 -0.015 (-0.82%)
|
09-21 10:54 |
|
Open: |
1.97 |
Pre. Close: |
1.82 |
|
High:
|
1.97 |
Low:
|
1.75 |
|
Volume:
|
19,606 |
Market Cap:
|
3(M) |
|
|
|
Technical analysis |
as of: 2023-09-21 10:44:25 AM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 2.69 One year: 3.07 |
| Support: |
Support1: 1.78 Support2: 1.48 |
| Resistance: |
Resistance1: 2.3 Resistance2: 2.63 |
| Pivot: |
2.16  |
| Moving Average: |
MA(5): 1.91 MA(20): 2.15
MA(100): 3.18 MA(250): 8.34 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 2.8 %D(3): 4.7 |
| RSI: |
RSI(14): 32.9 |
| 52-week: |
High: 16 Low: 1.78 |
| Average Vol(K): |
3-Month: 48 (K) 10-Days: 38 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AGRX ] has closed above bottom band by 13.9%. Bollinger Bands are 19.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.9 - 1.91 |
1.91 - 1.92 |
|
Low:
|
1.76 - 1.78 |
1.78 - 1.79 |
|
Close:
|
1.8 - 1.82 |
1.82 - 1.84 |
|
Company Description |
|
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey. |
Headline News |
Tue, 05 Sep 2023
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Marketscreener.com
Tue, 05 Sep 2023
Agile Therapeutics to Present at the H.C. Wainwright 25th - GlobeNewswire
Thu, 31 Aug 2023
Should You Buy Agile Therapeutics Inc (AGRX) Stock After it Has Gained 17.31% in a Week? - InvestorsObserver
Fri, 11 Aug 2023
Agile Therapeutics, Inc. (NASDAQ:AGRX) Q2 2023 Earnings Call Transcript - Yahoo Finance
Wed, 09 Aug 2023
Agile Therapeutics, Inc. (AGRX) Q2 2023 Earnings Call Transcript - Seeking Alpha
Wed, 26 Jul 2023
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023 - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
2 (M) |
| Shares Float |
2 (M) |
|
% Held by Insiders
|
3.4 (%) |
|
% Held by Institutions
|
1 (%) |
|
Shares Short
|
21 (K) |
|
Shares Short P.Month
|
71 (K) |
Stock Financials |
|
EPS
|
155.22 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-7.39 |
|
Profit Margin (%)
|
-116.9 |
|
Operating Margin (%)
|
-161.2 |
|
Return on Assets (ttm)
|
-72.5 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
158.8 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
8.45 |
|
EBITDA (p.s.)
|
-13.35 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-28 (M) |
|
Levered Free Cash Flow
|
-20 (M) |
Stock Valuations |
|
PE Ratio
|
0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-0.25 |
|
Price to Sales
|
0.21 |
|
Price to Cash Flow
|
-0.13 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
